Non-Hodgkin Lymphoma — Variants & evidence

Loading cancer entity…

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ACTB Mutation1
(oncogenic)	Diffuse Large B-Cell LymphomaCURATED_BROADER	Oncogenic	E	Supports Oncogenicity	4	submitted	EID11906 This study performed exome sequencing on 55 DLBCL tumor samples and identified several significantly mutated genes including ACTB. PMID 22343534 · Lohr et al., 2012 · Open in CIViC	civic
ALK F1174L + ALK Fusion1
Ceritinib	Anaplastic Large Cell Lymphoma	Predictive	D	Supports Resistance	3	submitted	EID12658 In an in vitro study, a FL5.12 cell line expressing NPM1-ALK (a known sensitizing alteration to crizotinib) and an ALK F1174L co-mutation, demonstrated resistance to ceritinib treatment (IC50: 140.45 … (full text at CIViC) PMID 27009859 · Amin et al., 2016 · Open in CIViC	civic
ALK G1269A + ALK Fusion1
Crizotinib	Anaplastic Large Cell Lymphoma	Predictive	D	Supports Resistance	3	submitted	EID12654 In an in vitro study, a FL5.12 cell line expressing NPM1-ALK (a known sensitizing alteration to crizotinib) and an ALK G1269A co-mutation, demonstrated resistance to crizotinib treatment (IC50: 871.75… (full text at CIViC) PMID 27009859 · Amin et al., 2016 · Open in CIViC	civic
ALK I11711
Crizotinib	Anaplastic Large Cell Lymphoma	Predictive	D	Supports Resistance	—	submitted	EID4612 In an in vitro study, Karpas299CR cells expressing NPM-ALK fusion (a known sensitizing alteration to crizotinib) and an ALK I1171T co-mutation, demonstrated resistance to crizotinib treatment compared… (full text at CIViC) PMID 24509625 · Zdzalik et al., 2014 · Open in CIViC	civic
ALK L1196Q1
Crizotinib	Anaplastic Large Cell Lymphoma	Predictive	D	Supports Resistance	3	submitted	EID4609 In an in vitro study, cell lines expressing NPM-ALK L1196Q, K299CR06 (endogenous expression) and Ba/F3 (overexpression), demonstrated resistance to crizotinib treatment (IC50: 948 nmol/L and 212 nmol/… (full text at CIViC) PMID 23239810 · Ceccon et al., 2013 · Open in CIViC	civic
ALK R214H1
Crizotinib	Nasal Type Extranodal NK/T-Cell Lymphoma	Predictive	C	Supports Sensitivity Response	—	submitted	EID4827 In a patient with nasal type extranodal NK/T-cell lymphoma harboring ALK R214H mutation, ALK R214H was associated with response to crizotinib monotherapy. Prior to identification of the ALK R214H muta… (full text at CIViC) PMID 27594191 · Thanarajasingam et al., 2016 · Open in CIViC	civic
ARID1A Mutation1
(oncogenic)	Diffuse Large B-Cell LymphomaCURATED_BROADER	Oncogenic	E	Supports Oncogenicity	4	submitted	EID11907 This study sequenced 73 DLBCL tumors (34 with matched constitutional DNA) and reported 322 genes they deemed recurrently mutated. Only genes that have been confirmed by other similar studies were adde… (full text at CIViC) PMID 23292937 · Zhang et al., 2013 · Open in CIViC	civic
ARID1A Q185*1
(oncogenic)	Burkitt Lymphoma	Oncogenic	E	Supports Oncogenicity	3	submitted	EID11813 Reported as significantly mutated in BL per the cited study. An arbitrarily selected variant from the study is included here. PMID 30617194 · Grande et al., 2019 · Open in CIViC	civic
ATM Mutation2
(oncogenic)	Diffuse Large B-Cell LymphomaCURATED_BROADER	Oncogenic	E	Supports Oncogenicity	4	submitted	EID11908 This study reportedly sequenced 1001 DLBCL tumors using whole exome sequencing. They reported 150 recurrently mutated genes. Only genes that have been confirmed by other similar studies were added to … (full text at CIViC) PMID 28985567 · Reddy et al., 2017 · Open in CIViC	civic
Olaparib	Mantle Cell Lymphoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID1907 Two ATM deficient mantle cell lymphoma (MCL) cell lines were more sensitive to PARP-1 inhibition with olaparib or PJ-34 than 4 other MCL cell lines. shRNA mediated ATM knockdown in a cell line increas… (full text at CIViC) PMID 20124459 · Williamson et al., 2010 · Open in CIViC	civic
ATM Oncogenic Mutations (loss of function alterations)1
(oncogenic)	Mantle Cell Lymphoma	Oncogenic	E	Supports Oncogenicity	4	submitted	EID11842 Mantle cell lymphoma is characterized by inactivation of the ATM gene PMID 10706620 · Schaffner et al., 2000 · Open in CIViC	civic
B2M Mutation2
(oncogenic)	Diffuse Large B-Cell LymphomaCURATED_BROADER	Oncogenic	E	Supports Oncogenicity	4	submitted	EID11930 This study used a combination of RNA-seq, whole genome and targeted sequencing to identify recurrently mutated genes in follicular and diffuse large B-cell lymphoma. They reported 30 genes that had si… (full text at CIViC) PMID 21796119 · Morin et al., 2011 · Open in CIViC	civic
〃	Mantle Cell Lymphoma	Oncogenic	E	Supports Oncogenicity	3	submitted	EID11891 Through a meta-analysis of exome and whole genome sequencing data, this study identified 18 genes that were significantly enriched for mutations in MCL. PMID 32160292 · Pararajalingam et al., 2020 · Open in CIViC	civic
BCL10 Mutation1
(oncogenic)	Diffuse Large B-Cell LymphomaCURATED_BROADER	Oncogenic	E	Supports Oncogenicity	4	submitted	EID11911 This study used a combination of RNA-seq, whole genome and targeted sequencing to identify recurrently mutated genes in follicular and diffuse large B-cell lymphoma. They reported 30 genes that had si… (full text at CIViC) PMID 21796119 · Morin et al., 2011 · Open in CIViC	civic
BCL11A Mutation1
(oncogenic)	Diffuse Large B-Cell LymphomaCURATED_BROADER	Oncogenic	E	Supports Oncogenicity	4	submitted	EID11935 The authors analyzed 304 primary DLBCLs using whole exome sequencing and targeted sequencing. This one one of the genes they identified as significantly enriched for somatic mutations. PMID 29713087 · Chapuy et al., 2018 · Open in CIViC	civic
BCL2 F104I2
Venetoclax	Follicular Lymphoma	Predictive	C	Supports Resistance	2	accepted	EID8375 This study identified BCL2 F104I mutation in one Follicular Lymphoma patient who developed resistance to venetoclax. Codon 104 is located at the venetoclax binding site of BCL2. PMID 31234236 · Blombery et al., 2019 · Open in CIViC	civic
〃	Follicular Lymphoma	Predictive	D	Supports Resistance	3	accepted	EID8376 Rs4;11 cells overexpressing BCL2 F104I exhibited >40-fold greater resistance to venetoclax after 24-hour treatment (IC50 not reached) than Rs4;11 overexpressing BCL2 WT cells as determined by cell tit… (full text at CIViC) PMID 31234236 · Blombery et al., 2019 · Open in CIViC	civic
BCL2 Mutation1
(prognostic)	Follicular Lymphoma	Prognostic	B	Supports Poor Outcome	3	accepted	EID5992 In a multivariate analysis, BCL2 mutations and high FL international prognostic index were independent risk factors for transformation and death due to lymphoma. Some mutant Bcl-2 proteins exhibited e… (full text at CIViC) PMID 25452615 · Correia et al., 2015 · Open in CIViC	civic
BCL2 Overexpression2
(prognostic)	Diffuse Large B-Cell LymphomaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	4	accepted	EID423 In patients with Diffuse Large B-Cell Lymphoma, those with increased levels of BCL2 were shown to have decreased overall, disease-free, and relapse-free survival. PMID 9207459 · Gascoyne et al., 1997 · Open in CIViC	civic
〃	Diffuse Large B-Cell LymphomaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	4	rejected	EID424 In patients with Diffuse Large B-Cell Lymphoma, those with increased levels of BCL2 were shown to have decreased OS, DFS, and RFS. PMID 9207459 · Gascoyne et al., 1997 · Open in CIViC	civic
BCL2 reg_e@[IGH]::BCL22
(diagnostic)	Follicular Lymphoma	Diagnostic	B	Supports Positive	5	submitted	EID11808 This translocation is a hallmark feature of follicular lymphoma. Although it is not present in every case, it is one of the most common genetic features of FL. FISH or IHC staining for BCL2 is part of… (full text at CIViC) PMID 3537802 · Yunis et al., 1987 · Open in CIViC	civic
〃	Diffuse Large B-Cell LymphomaCURATED_BROADER	Diagnostic	B	Supports Positive	4	accepted	EID407 The t(14;18) transloaction of BCL2 is shown to be associated with germinal-center B-cell–like diffuse large-B-cell lymphomas. PMID 12075054 · Rosenwald et al., 2002 · Open in CIViC	civic
BCL2 Translocation1
(diagnostic)	High Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements	Diagnostic	A	Supports Positive	4	submitted	EID11810 The combination of these genetic features are diagnostic for this newly defined entity as per the latest ICC and WHO guidelines PMID 35653592 · Campo et al., 2022 · Open in CIViC	civic
BCL6 Mutation1
(oncogenic)	Diffuse Large B-Cell LymphomaCURATED_BROADER	Oncogenic	E	Supports Oncogenicity	4	submitted	EID11915 This study used a combination of RNA-seq, whole genome and targeted sequencing to identify recurrently mutated genes in follicular and diffuse large B-cell lymphoma. They reported 30 genes that had si… (full text at CIViC) PMID 21796119 · Morin et al., 2011 · Open in CIViC	civic
BCL7A mutation2
(oncogenic)	Diffuse Large B-Cell LymphomaCURATED_BROADER	Oncogenic	E	Supports Oncogenicity	4	submitted	EID11936 This study reportedly sequenced 1001 DLBCL tumors using whole exome sequencing. They reported 150 recurrently mutated genes. Only genes that have been confirmed by other similar studies were added to … (full text at CIViC) PMID 28985567 · Reddy et al., 2017 · Open in CIViC	civic
〃	Burkitt Lymphoma	Oncogenic	E	Supports Oncogenicity	3	submitted	EID11816 Mutations in this gene have been described in several studies including the one referenced here. PMID 30617194 · Grande et al., 2019 · Open in CIViC	civic
BIRC3 mutation1
(oncogenic)	Mantle Cell Lymphoma	Oncogenic	E	Supports Oncogenicity	3	submitted	EID11843 BIRC3 mutations have been described in MCL in multiple studies PMID 32160292 · Pararajalingam et al., 2020 · Open in CIViC	civic
BIRC6 Mutation1
(oncogenic)	Diffuse Large B-Cell LymphomaCURATED_BROADER	Oncogenic	E	Supports Oncogenicity	4	submitted	EID12000 This study reportedly sequenced 1001 DLBCL tumors using whole exome sequencing. They reported 150 recurrently mutated genes. Some concerns about the validity of the results have been expressed in subs… (full text at CIViC) PMID 28985567 · Reddy et al., 2017 · Open in CIViC	civic
BMP7 mutation1
(oncogenic)	Burkitt Lymphoma	Oncogenic	E	Supports Oncogenicity	2	submitted	EID11837 Observed mutated in BL in more than one genomic data set PMID 31558468 · Panea et al., 2019 · Open in CIViC	civic
BRAF Mutation1
(oncogenic)	Diffuse Large B-Cell LymphomaCURATED_BROADER	Oncogenic	E	Supports Oncogenicity	4	submitted	EID11937 This study performed exome sequencing on 55 DLBCL tumor samples and identified several significantly mutated genes including BRAF. PMID 22343534 · Lohr et al., 2012 · Open in CIViC	civic
BRAF V600E12
(diagnostic)	Hairy Cell Leukemia	Diagnostic	B	Supports Positive	4	accepted	EID1127 In 47 patients with Hairy Cell Leukemia, sequencing discovered a V600E mutation in all 47 of the sequenced patients. PMID 21663470 · Tiacci et al., 2011 · Open in CIViC	civic
(prognostic)	Multiple Myeloma	Prognostic	B	Supports Poor Outcome	3	accepted	EID463 In patients with multiple myeloma, those with BRAF V600E had shorter overall survival than wild-type. PMID 23612012 · Andrulis et al., 2013 · Open in CIViC	civic
Vemurafenib	Hairy Cell Leukemia	Predictive	B	Supports Sensitivity Response	3	submitted	EID11315 In these two phase II studies (Italy and U.S. locations), BRAF V600E-mutant hairy-cell leukemia was treated with vemurafenib at a dose of 960 mg twice daily to investigate its efficacy. The overall re…
BTG1 Mutation1
(oncogenic)	Diffuse Large B-Cell LymphomaCURATED_BROADER	Oncogenic	E	Supports Oncogenicity	4	submitted	EID11918 This study used a combination of RNA-seq, whole genome and targeted sequencing to identify recurrently mutated genes in follicular and diffuse large B-cell lymphoma. They reported 30 genes that had si… (full text at CIViC) PMID 21796119 · Morin et al., 2011 · Open in CIViC	civic
BTG2 Mutation1
(oncogenic)	Diffuse Large B-Cell LymphomaCURATED_BROADER	Oncogenic	E	Supports Oncogenicity	4	submitted	EID11914 This study used a combination of RNA-seq, whole genome and targeted sequencing to identify recurrently mutated genes in follicular and diffuse large B-cell lymphoma. They reported 30 genes that had si… (full text at CIViC) PMID 21796119 · Morin et al., 2011 · Open in CIViC	civic
BTK MUTATION1
(oncogenic)	Diffuse Large B-Cell LymphomaCURATED_BROADER	Oncogenic	E	Supports Oncogenicity	4	submitted	EID11938 This study reportedly sequenced 1001 DLBCL tumors using whole exome sequencing. They reported 150 recurrently mutated genes. Only genes that have been confirmed by other similar studies were added to … (full text at CIViC) PMID 28985567 · Reddy et al., 2017 · Open in CIViC	civic
CARD11 MUTATION3
(prognostic)	Diffuse Large B-Cell LymphomaCURATED_BROADER	Prognostic	D	Supports Poor Outcome	4	rejected	EID8344 The signalling adaptor CARD11 is required for constitutive NF-kappaB pathway activity and survival in ABC DLBCL. Roughly 10% of ABC DLBCLs have mutant CARD11 isoforms that activate NF-kappaB, but the … (full text at CIViC) PMID 20054396 · Davis et al., 2010 · Open in CIViC	civic
(oncogenic)	Diffuse Large B-Cell LymphomaCURATED_BROADER	Oncogenic	E	Supports Oncogenicity	4	submitted	EID11932 This study used a combination of RNA-seq, whole genome and targeted sequencing to identify recurrently mutated genes in follicular and diffuse large B-cell lymphoma. They reported 30 genes that had si… (full text at CIViC) PMID 21796119 · Morin et al., 2011 · Open in CIViC	civic
〃	Mantle Cell Lymphoma	Oncogenic
CCND1 Overexpression2
(prognostic)	Mantle Cell Lymphoma	Prognostic	B	Supports Poor Outcome	4	accepted	EID358 Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in mantle cell lymphoma. PMID 17891190 · Jares et al., 2007 · Open in CIViC	civic
Bortezomib	Multiple Myeloma	Predictive	C	Supports Sensitivity Response	3	submitted	EID7788 Bone marrow specimens from 20/47 patients treated with bortezomib were analyzed. Researchers analyzed CCND1, CCND2, and CCND3 expression using real-time PCR. Results show all patients with CCND1 ove… (full text at CIViC) PMID 20578819 · Ngo et al., 2010 · Open in CIViC	civic

Therapy

Cancer

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

ACTB Mutation1

(oncogenic)

Diffuse Large B-Cell LymphomaCURATED_BROADER

Oncogenic

Supports Oncogenicity

submitted

EID11906

This study performed exome sequencing on 55 DLBCL tumor samples and identified several significantly mutated genes including ACTB.

PMID 22343534 · Lohr et al., 2012 · Open in CIViC

civic

ALK F1174L + ALK Fusion1

Ceritinib

Anaplastic Large Cell Lymphoma

Predictive

Supports Resistance

submitted

EID12658

In an in vitro study, a FL5.12 cell line expressing NPM1-ALK (a known sensitizing alteration to crizotinib) and an ALK F1174L co-mutation, demonstrated resistance to ceritinib treatment (IC50: 140.45 … (full text at CIViC)

PMID 27009859 · Amin et al., 2016 · Open in CIViC

civic

ALK G1269A + ALK Fusion1

Crizotinib

Anaplastic Large Cell Lymphoma

Predictive

Supports Resistance

submitted

EID12654

In an in vitro study, a FL5.12 cell line expressing NPM1-ALK (a known sensitizing alteration to crizotinib) and an ALK G1269A co-mutation, demonstrated resistance to crizotinib treatment (IC50: 871.75… (full text at CIViC)

PMID 27009859 · Amin et al., 2016 · Open in CIViC

civic

ALK I11711

Crizotinib

Anaplastic Large Cell Lymphoma

Predictive

Supports Resistance

—

submitted

EID4612

In an in vitro study, Karpas299CR cells expressing NPM-ALK fusion (a known sensitizing alteration to crizotinib) and an ALK I1171T co-mutation, demonstrated resistance to crizotinib treatment compared… (full text at CIViC)

PMID 24509625 · Zdzalik et al., 2014 · Open in CIViC

civic

ALK L1196Q1

Crizotinib

Anaplastic Large Cell Lymphoma

Predictive

Supports Resistance

submitted

EID4609

In an in vitro study, cell lines expressing NPM-ALK L1196Q, K299CR06 (endogenous expression) and Ba/F3 (overexpression), demonstrated resistance to crizotinib treatment (IC50: 948 nmol/L and 212 nmol/… (full text at CIViC)

PMID 23239810 · Ceccon et al., 2013 · Open in CIViC

civic

ALK R214H1

Crizotinib

Nasal Type Extranodal NK/T-Cell Lymphoma

Predictive

Supports Sensitivity Response

—

submitted

EID4827

In a patient with nasal type extranodal NK/T-cell lymphoma harboring ALK R214H mutation, ALK R214H was associated with response to crizotinib monotherapy. Prior to identification of the ALK R214H muta… (full text at CIViC)

PMID 27594191 · Thanarajasingam et al., 2016 · Open in CIViC

civic

ARID1A Mutation1

(oncogenic)

Diffuse Large B-Cell LymphomaCURATED_BROADER

Oncogenic

Supports Oncogenicity

submitted

EID11907

This study sequenced 73 DLBCL tumors (34 with matched constitutional DNA) and reported 322 genes they deemed recurrently mutated. Only genes that have been confirmed by other similar studies were adde… (full text at CIViC)

PMID 23292937 · Zhang et al., 2013 · Open in CIViC

civic

ARID1A Q185*1

(oncogenic)

Burkitt Lymphoma

Oncogenic

Supports Oncogenicity

submitted

EID11813

Reported as significantly mutated in BL per the cited study. An arbitrarily selected variant from the study is included here.

PMID 30617194 · Grande et al., 2019 · Open in CIViC

civic

ATM Mutation2

(oncogenic)

Diffuse Large B-Cell LymphomaCURATED_BROADER

Oncogenic

Supports Oncogenicity

submitted

EID11908

This study reportedly sequenced 1001 DLBCL tumors using whole exome sequencing. They reported 150 recurrently mutated genes. Only genes that have been confirmed by other similar studies were added to … (full text at CIViC)

PMID 28985567 · Reddy et al., 2017 · Open in CIViC

civic

Olaparib

Mantle Cell Lymphoma

Predictive

Supports Sensitivity Response

accepted

EID1907

Two ATM deficient mantle cell lymphoma (MCL) cell lines were more sensitive to PARP-1 inhibition with olaparib or PJ-34 than 4 other MCL cell lines. shRNA mediated ATM knockdown in a cell line increas… (full text at CIViC)

PMID 20124459 · Williamson et al., 2010 · Open in CIViC

civic

ATM Oncogenic Mutations (loss of function alterations)1

(oncogenic)

Mantle Cell Lymphoma

Oncogenic

Supports Oncogenicity

submitted

EID11842

Mantle cell lymphoma is characterized by inactivation of the ATM gene

PMID 10706620 · Schaffner et al., 2000 · Open in CIViC

civic

B2M Mutation2

(oncogenic)

Diffuse Large B-Cell LymphomaCURATED_BROADER

Oncogenic

Supports Oncogenicity

submitted

EID11930

This study used a combination of RNA-seq, whole genome and targeted sequencing to identify recurrently mutated genes in follicular and diffuse large B-cell lymphoma. They reported 30 genes that had si… (full text at CIViC)

PMID 21796119 · Morin et al., 2011 · Open in CIViC

civic

〃

Mantle Cell Lymphoma

Oncogenic

Supports Oncogenicity

submitted

EID11891

Through a meta-analysis of exome and whole genome sequencing data, this study identified 18 genes that were significantly enriched for mutations in MCL.

PMID 32160292 · Pararajalingam et al., 2020 · Open in CIViC

civic

BCL10 Mutation1

(oncogenic)

Diffuse Large B-Cell LymphomaCURATED_BROADER

Oncogenic

Supports Oncogenicity

submitted

EID11911

PMID 21796119 · Morin et al., 2011 · Open in CIViC

civic

BCL11A Mutation1

(oncogenic)

Diffuse Large B-Cell LymphomaCURATED_BROADER

Oncogenic

Supports Oncogenicity

submitted

EID11935

The authors analyzed 304 primary DLBCLs using whole exome sequencing and targeted sequencing. This one one of the genes they identified as significantly enriched for somatic mutations.

PMID 29713087 · Chapuy et al., 2018 · Open in CIViC

Predictive

Supports Resistance

accepted

EID8375

This study identified BCL2 F104I mutation in one Follicular Lymphoma patient who developed resistance to venetoclax. Codon 104 is located at the venetoclax binding site of BCL2.

PMID 31234236 · Blombery et al., 2019 · Open in CIViC

civic

〃

Follicular Lymphoma

Predictive

Supports Resistance

accepted

EID8376

Rs4;11 cells overexpressing BCL2 F104I exhibited >40-fold greater resistance to venetoclax after 24-hour treatment (IC50 not reached) than Rs4;11 overexpressing BCL2 WT cells as determined by cell tit… (full text at CIViC)

PMID 31234236 · Blombery et al., 2019 · Open in CIViC

civic

BCL2 Mutation1

(prognostic)

Follicular Lymphoma

Prognostic

Supports Poor Outcome

accepted

EID5992

In a multivariate analysis, BCL2 mutations and high FL international prognostic index were independent risk factors for transformation and death due to lymphoma. Some mutant Bcl-2 proteins exhibited e… (full text at CIViC)

PMID 25452615 · Correia et al., 2015 · Open in CIViC

civic

BCL2 Overexpression2

(prognostic)

Diffuse Large B-Cell LymphomaCURATED_BROADER

Prognostic

Supports Poor Outcome

accepted

EID423

In patients with Diffuse Large B-Cell Lymphoma, those with increased levels of BCL2 were shown to have decreased overall, disease-free, and relapse-free survival.

PMID 9207459 · Gascoyne et al., 1997 · Open in CIViC

civic

〃

Diffuse Large B-Cell LymphomaCURATED_BROADER

Prognostic

Supports Poor Outcome

rejected

EID424

In patients with Diffuse Large B-Cell Lymphoma, those with increased levels of BCL2 were shown to have decreased OS, DFS, and RFS.

PMID 9207459 · Gascoyne et al., 1997 · Open in CIViC

civic

BCL2 reg_e@[IGH]::BCL22

(diagnostic)

Follicular Lymphoma

Diagnostic

Supports Positive

submitted

EID11808

This translocation is a hallmark feature of follicular lymphoma. Although it is not present in every case, it is one of the most common genetic features of FL. FISH or IHC staining for BCL2 is part of… (full text at CIViC)

PMID 3537802 · Yunis et al., 1987 · Open in CIViC

civic

〃

Diffuse Large B-Cell LymphomaCURATED_BROADER

Diagnostic

Supports Positive

accepted

EID407

The t(14;18) transloaction of BCL2 is shown to be associated with germinal-center B-cell–like diffuse large-B-cell lymphomas.

PMID 12075054 · Rosenwald et al., 2002 · Open in CIViC

civic

BCL2 Translocation1

(diagnostic)

High Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements

Diagnostic

Supports Positive

submitted

EID11810

The combination of these genetic features are diagnostic for this newly defined entity as per the latest ICC and WHO guidelines

PMID 35653592 · Campo et al., 2022 · Open in CIViC

civic

BCL6 Mutation1

(oncogenic)

Diffuse Large B-Cell LymphomaCURATED_BROADER

Oncogenic

Supports Oncogenicity

submitted

EID11915

PMID 21796119 · Morin et al., 2011 · Open in CIViC

civic

BCL7A mutation2

(oncogenic)

Diffuse Large B-Cell LymphomaCURATED_BROADER

Oncogenic

Supports Oncogenicity

submitted

EID11936

PMID 28985567 · Reddy et al., 2017 · Open in CIViC

civic

〃

Burkitt Lymphoma

Oncogenic

Supports Oncogenicity

submitted

EID11816

Mutations in this gene have been described in several studies including the one referenced here.

PMID 30617194 · Grande et al., 2019 · Open in CIViC

civic

BIRC3 mutation1

(oncogenic)

Mantle Cell Lymphoma

Oncogenic

Supports Oncogenicity

submitted

EID11843

BIRC3 mutations have been described in MCL in multiple studies

PMID 32160292 · Pararajalingam et al., 2020 · Open in CIViC

civic

BIRC6 Mutation1

(oncogenic)

Diffuse Large B-Cell LymphomaCURATED_BROADER

Oncogenic

Supports Oncogenicity

submitted

EID12000

This study reportedly sequenced 1001 DLBCL tumors using whole exome sequencing. They reported 150 recurrently mutated genes. Some concerns about the validity of the results have been expressed in subs… (full text at CIViC)

PMID 28985567 · Reddy et al., 2017 · Open in CIViC

civic

BMP7 mutation1

(oncogenic)

Burkitt Lymphoma

Oncogenic

Supports Oncogenicity

submitted

EID11837

Observed mutated in BL in more than one genomic data set

PMID 31558468 · Panea et al., 2019 · Open in CIViC

civic

BRAF Mutation1

(oncogenic)

Diffuse Large B-Cell LymphomaCURATED_BROADER

Oncogenic

Supports Oncogenicity

submitted

EID11937

This study performed exome sequencing on 55 DLBCL tumor samples and identified several significantly mutated genes including BRAF.

PMID 22343534 · Lohr et al., 2012 · Open in CIViC

civic

BRAF V600E12

(diagnostic)

Hairy Cell Leukemia

Diagnostic

Supports Positive

accepted

EID1127

In 47 patients with Hairy Cell Leukemia, sequencing discovered a V600E mutation in all 47 of the sequenced patients.

PMID 21663470 · Tiacci et al., 2011 · Open in CIViC

civic

(prognostic)

Multiple Myeloma

Prognostic

Supports Poor Outcome

accepted

EID463

In patients with multiple myeloma, those with BRAF V600E had shorter overall survival than wild-type.

PMID 23612012 · Andrulis et al., 2013 · Open in CIViC

civic

Vemurafenib

Hairy Cell Leukemia

Predictive

Supports Sensitivity Response

submitted

EID11315

In these two phase II studies (Italy and U.S. locations), BRAF V600E-mutant hairy-cell leukemia was treated with vemurafenib at a dose of 960 mg twice daily to investigate its efficacy. The overall re…

BTG1 Mutation1

(oncogenic)

Diffuse Large B-Cell LymphomaCURATED_BROADER

Oncogenic

Supports Oncogenicity

submitted

EID11918

PMID 21796119 · Morin et al., 2011 · Open in CIViC

civic

BTG2 Mutation1

(oncogenic)

Diffuse Large B-Cell LymphomaCURATED_BROADER

Oncogenic

Supports Oncogenicity

submitted

EID11914

PMID 21796119 · Morin et al., 2011 · Open in CIViC

civic

BTK MUTATION1

(oncogenic)

Diffuse Large B-Cell LymphomaCURATED_BROADER

Oncogenic

Supports Oncogenicity

submitted

EID11938

PMID 28985567 · Reddy et al., 2017 · Open in CIViC

civic

CARD11 MUTATION3

(prognostic)

Diffuse Large B-Cell LymphomaCURATED_BROADER

Prognostic

Supports Poor Outcome

rejected

EID8344

The signalling adaptor CARD11 is required for constitutive NF-kappaB pathway activity and survival in ABC DLBCL. Roughly 10% of ABC DLBCLs have mutant CARD11 isoforms that activate NF-kappaB, but the … (full text at CIViC)

PMID 20054396 · Davis et al., 2010 · Open in CIViC

civic

(oncogenic)

Diffuse Large B-Cell LymphomaCURATED_BROADER

Oncogenic

Supports Oncogenicity

submitted

EID11932

PMID 21796119 · Morin et al., 2011 · Open in CIViC

civic

〃

Mantle Cell Lymphoma

Oncogenic

CCND1 Overexpression2

(prognostic)

Mantle Cell Lymphoma

Prognostic

Supports Poor Outcome

accepted

EID358

Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in mantle cell lymphoma.

PMID 17891190 · Jares et al., 2007 · Open in CIViC

civic

Bortezomib

Multiple Myeloma

Predictive

Supports Sensitivity Response

submitted

EID7788

Bone marrow specimens from 20/47 patients treated with bortezomib were analyzed. Researchers analyzed CCND1, CCND2, and CCND3 expression using real-time PCR. Results show all patients with CCND1 ove… (full text at CIViC)

PMID 20578819 · Ngo et al., 2010 · Open in CIViC

civic

Curated clinical evidence by variant and therapy